Daily Archives: February 14, 2019


Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Deuterated Norketamine and Related Compounds

Southborough, MA, February 14, 2019 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, announced that its patent application for deuterated norketamine and related NMDA receptor modulators was allowed for issuance as a new patent by the U.S. Patent and Trademark Office. This patent is set to expire in 2035 and further strengthens Amorsa’s intellectual property portfolio, which is wholly owned by the Company. Ketamine, currently only FDA-approved for use as an anesthetic, has been shown in several randomized, placebo-controlled trials to produce rapid antidepressant effects in patients with treatment-resistant depression and More